From Theory to Practice: Applying Curren
✍
Edward D. Gomperts; Jan Astermark; Alessandro Gringeri; Jerome Teitel
📂
Article
📅
2008
🏛
Elsevier Science
🌐
English
⚖ 666 KB
Two bypassing agents are currently available to circumvent the need for factor FVIII in hemophilia A patients with inhibitors: the activated prothrombin complex FEIBA VH and recombinant activated factor VII (NovoSeven ® ). Both products are highly effective in controlling bleeding in the presence of